Spots Global Cancer Trial Database for adoptive cell therapy
Every month we try and update this database with for adoptive cell therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT06121557 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Chemotherapeuti... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Harvesting Cells for Experimental Cancer Treatments | NCT00068003 | Melanoma Gastrointestina... Metastatic Canc... Breast Cancer Non-Small Cell ... | Anti-CD19 CAR P... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | NCT06358053 | Cervical Cancer Anal Cancer Head and Neck C... Other Solid Tum... | CRTE7A2-01 TCR-... | 18 Years - 65 Years | Corregene Biotechnology Co., Ltd | |
| Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors | NCT05141474 | Epithelial Tumo... Malignant Solid... | NEXTGEN-TIL Non-myeloablati... Interleukin-2 | 18 Years - | Vall d'Hebron Institute of Oncology | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | NCT06121570 | Breast Neoplasm... | Sentinel Lymph ... Doxorubicin Epirubicin Cyclophosphamid... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Nab-paclitaxel | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | NCT01585415 | Metastatic Canc... Melanoma | Vemurafenib Young TIL Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| BATs in Patients With Breast Cancer and Leptomeningeal Metastases | NCT03661424 | Breast Cancer F... Leptomeningeal ... | HER2 BATs | 18 Years - | University of Virginia | |
| Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma | NCT04052334 | Sarcoma | TIL Interleukin-2 Fludarabine Cyclophosphamid... | 18 Years - 39 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| BATs Treatment for Pancreatic Cancer, Phase Ib/II | NCT03269526 | Locally Advance... Metastatic Panc... | EGFR BATs after... | 18 Years - | University of Virginia | |
| Harvesting Cells for Experimental Cancer Treatments | NCT00068003 | Melanoma Gastrointestina... Metastatic Canc... Breast Cancer Non-Small Cell ... | Anti-CD19 CAR P... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | NCT06204991 | Melanoma Stage ... Melanoma Stage ... Melanoma | ADP-TILIL7 Cyclophosphamid... Fludarabine Pho... Proleukin | 18 Years - 75 Years | Herlev Hospital | |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT02948426 | Fallopian Tube ... Ovarian Cancer Primary Periton... | Autologous Mono... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | NCT05908643 | Colorectal Canc... | pTTL | 18 Years - | Neogap Therapeutics AB | |
| Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma | NCT01005745 | Metastatic Mela... | Surgery Administration ... Adoptive Cell T... High Dose IL-2 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | NCT04611126 | Metastatic Ovar... Metastatic Fall... Peritoneal Canc... | Ipilimumab Cyclophosphamid Fludarabine Pho... Tumor Infiltrat... Nivolumab Relatlimab | 18 Years - 75 Years | Herlev Hospital | |
| Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | NCT04146298 | Pancreatic Canc... Pancreatic Neop... Pancreatic Duct... Advanced Cancer | Cyclophosphamid... Fludarabine Mutant KRAS G12... Anti-PD-1 monoc... | 18 Years - 75 Years | Changhai Hospital | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| ACT-TIL and ANV419 for Advanced Melanoma. | NCT05869539 | Advanced Melano... | Combination of ... | 18 Years - | University Hospital, Basel, Switzerland | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | NCT03391778 | Neoplasms | GSK adoptive ce... | - | GlaxoSmithKline | |
| ACT-TIL and ANV419 for Advanced Melanoma. | NCT05869539 | Advanced Melano... | Combination of ... | 18 Years - | University Hospital, Basel, Switzerland | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab | NCT04536922 | Metastatic HPV-... | Cyclophosphamid... Fludarabine Aldesleukin Pembrolizumab (... Individual Pati... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | NCT01236573 | Skin Cancer Metastatic Mela... | Fludarabine Cyclophosphamid... IL-12 transduce... | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT06121557 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Chemotherapeuti... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... | NCT01319565 | Metastatic Mela... Skin Cancer | Aldesleukin Cyclophosphamid... Fludarabine Young TIL Total Body Irra... | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | NCT04146298 | Pancreatic Canc... Pancreatic Neop... Pancreatic Duct... Advanced Cancer | Cyclophosphamid... Fludarabine Mutant KRAS G12... Anti-PD-1 monoc... | 18 Years - 75 Years | Changhai Hospital | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | NCT06121570 | Breast Neoplasm... | Sentinel Lymph ... Doxorubicin Epirubicin Cyclophosphamid... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Nab-paclitaxel | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | NCT03158935 | Advanced Ovaria... Malignant Melan... | Cyclophosphamid... Fludarabine Pembrolizumab Tumor-Infiltrat... Interleukin-2 (... | 18 Years - | University Health Network, Toronto | |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | NCT05194735 | Gynecologic Can... Colorectal Canc... Pancreatic Canc... Non-small Cell ... Cholangiocarcin... Ovarian Cancer Endometrial Can... Ovarian Carcino... Ovary Neoplasm Squamous Cell L... Adenocarcinoma ... Adenosquamous C... | Neoantigen spec... Aldesleukin (IL... | 18 Years - | Alaunos Therapeutics | |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT05981001 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Nab-paclitaxel Gemcitabine Carboplatin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab | NCT04536922 | Metastatic HPV-... | Cyclophosphamid... Fludarabine Aldesleukin Pembrolizumab (... Individual Pati... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab | NCT04536922 | Metastatic HPV-... | Cyclophosphamid... Fludarabine Aldesleukin Pembrolizumab (... Individual Pati... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | NCT01993719 | Metastatic Mela... | Aldesleukin Fludarabine Fludarabine Cyclophosphamid... Cyclophosphamid... Cyclophosphamid... Young TIL Pembrolizumab | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | NCT02111850 | Cervical Cancer Renal Cancer Urothelial Canc... Melanoma Breast Cancer | Anti-MAGE-A3-DP... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT05981001 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Nab-paclitaxel Gemcitabine Carboplatin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | NCT05908643 | Colorectal Canc... | pTTL | 18 Years - | Neogap Therapeutics AB | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | NCT04904185 | Malignant Melan... | Cyclophosphamid... Fludarabine Pho... Multiple Antige... Pembrolizumab | 18 Years - 75 Years | Herlev Hospital | |
| Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT05981001 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Nab-paclitaxel Gemcitabine Carboplatin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of DeTIL-0255 in Adults With Advanced Malignancies | NCT05107739 | Platinum-resist... Endometrial Can... Cervical Cancer | Drug Product De... | 18 Years - 70 Years | Nurix Therapeutics, Inc. | |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | NCT05908643 | Colorectal Canc... | pTTL | 18 Years - | Neogap Therapeutics AB | |
| A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | NCT03166878 | B Cell Leukemia B Cell Lymphoma | UCART019 | 12 Years - 75 Years | Chinese PLA General Hospital | |
| CISH Inactivated TILs in the Treatment of NSCLC | NCT05566223 | Carcinoma, Non-... Metastatic Non ... Stage IV Non-sm... Squamous Cell L... Adenocarcinoma ... Large Cell Lung... | Fludarabine Cyclophosphamid... CISH Inactivate... Aldesleukin Pembrolizumab | 18 Years - 75 Years | Intima Bioscience, Inc. | |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | NCT03158935 | Advanced Ovaria... Malignant Melan... | Cyclophosphamid... Fludarabine Pembrolizumab Tumor-Infiltrat... Interleukin-2 (... | 18 Years - | University Health Network, Toronto | |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | NCT00924001 | Melanoma Malignant Melan... Melanoma, Exper... | DMF5 Melanoma R... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | NCT00328861 | Metastatic Mela... Metastatic Kidn... | Natural Killer ... IL-2 Cyclophosphamid... Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | NCT02111850 | Cervical Cancer Renal Cancer Urothelial Canc... Melanoma Breast Cancer | Anti-MAGE-A3-DP... Cyclophosphamid... Fludarabine Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | NCT06060613 | Tumor Skin Metastatic Mela... Melanoma Lung Cancer Metastatic Lung... Non Small Cell ... Metastatic Non ... | OBX-115 | 18 Years - | Obsidian Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
